

# APPLICATION FOR MANUFACTURERS PRICE BY SPECIAL AUTHORITY

**APPLICANT** (stamp or sticker acceptable)      **PATIENT NHI:** .....      **REFERRER Reg No:** .....

Reg No: .....      First Names: .....      First Names: .....

Name: .....      Surname: .....      Surname: .....

Address: .....      DOB: .....      Address: .....

.....      Address: .....      .....

.....      .....

Fax Number: .....      Fax Number: .....

## Atorvastatin

### INITIAL APPLICATION

Applications only from a relevant specialist, or general practitioner. Approvals valid without further renewal unless notified.

**Prerequisites** (tick boxes, and write the data requested in the space provided where appropriate)

Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years  
and

Patient has severe documented intolerance to simvastatin (blood tests are not required)  
or

Patient has been compliant with a dose of simvastatin of 80 mg per day for at least 2 months  
and

Patient has venous CABG  
and  
LDL cholesterol test 1: ..... ≥ 2 mmol/litre  
and  
LDL cholesterol test 2: ..... ≥ 2 mmol/litre (at least 1 week after test 1)

or  
 Patient does not have venous CABG  
and  
LDL cholesterol test 1: ..... ≥ 2.5 mmol/litre  
and  
LDL cholesterol test 2: ..... ≥ 2.5 mmol/litre (at least 1 week after test 1)

**Note:**

To confirm that cholesterol levels are not still improving, two lipid tests must be carried out during treatment with simvastatin 80 mg, and have results for LDL cholesterol that have reduced by <10% in the second test. The tests must be carried out while the patient is in a fasted state (with the exception of patients with IDDM).

The following indications of intolerance to simvastatin, are known as class effects for all statins, and hence are likely to mean that the patient may also be intolerant of atorvastatin:

- Constipation, flatulence (may occur in >1% of patients)
- Asthenia, abdominal pain, headache (may occur in >1% of patients)
- Myopathy, rhabdomyolysis (may occur in <3% of patients)
- Elevated serum transaminase levels (may occur in <1% of patients)

Statins have been shown to be generally well tolerated in clinical studies, with the rate of discontinuation due to adverse reactions being less than 5%, and similar to the discontinuation rate for patients taking a placebo.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....